RISK PREDICTION OF COVID-19 SEVERITY USING URINARY L-FABP AND THE SOFA SCORE

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/4688017c8194c450e39903f9e6a4c95a.pdf
RISK PREDICTION OF COVID-19 SEVERITY USING URINARY L-FABP AND THE SOFA SCORE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Kanako
Terakawa
Kanako Terakawa terakawa.k@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Department of Nephrology Tokyo Japan *
Daisuke Katagiri katagiri.d@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Department of Nephrology Tokyo Japan -
Yusuke Asai asai.yu@jihs.go.jp Japan Institute for Health Security Center for Clinical Sciences Tokyo Japan -
Masahiro Ishikane ishikane.m@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Disease Control and Prevention Center Tokyo Japan -
Norio Ohmagari ohmagari@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Disease Control and Prevention Center Tokyo Japan -
Minami Suzuki suzuki.min@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Department of Nephrology Tokyo Japan -
Masayuki Hojo hojo.m@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Department of Respiratory Medicine Tokyo Japan -
Hideki Takano takano.h@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Department of Nephrology Tokyo Japan -
Katsushi Tokunaga tokunaga.ka@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Genome Medical Science Project Tokyo Japan -
Takeshi Sugaya takeshi-sugaya@marianna-u.ac.jp St. Marianna University School of Medicine Division of Nephrology and Hypertension Kanagawa Japan -
Eisei Noiri noiri.e@jihs.go.jp National Center for Global Health and Medicine, Japan Institute for Health Security Central Biobank, National Center Biobank Network Tokyo Japan -
-
-
-
-